RFA Treatment for Papillary Thyroid Microcarcinoma Cohort

Status: Recruiting
Location: See location...
Intervention Type: Procedure
Study Type: Observational
SUMMARY

Thyroid surgery has always been the mainstay of treatment for thyroid cancer. Thyroid surgery carries a low risk of complications that include recurrent or superior laryngeal nerve injury leading to voice changes, hypoparathyroidism, hypothyroidism with need for thyroid hormone supplementation, and unsightly scarring. Although many patients with thyroid cancer find these risks acceptable, these risks are sometimes less acceptable to patients with benign disease. In an era when the medical field is treating thyroid diseases less aggressively, there is a pressing need to identify approaches to treat indolent malignant disease less invasively. The purpose of this observational study is to evaluate the efficacy and safety of Radiofrequency Ablation (RFA) for treatment of Papillary Thyroid Microcarcinoma (PTMC) in patients that have already agreed to RFA procedure based on treating physician recommendation. This is a data collection study in which we ask participants to give us access to information generated before and after RFA treatment of their condition. The RFA procedure uses image guidance to place an electrode through the skin into the target tumor. In RFA, high-frequency electrical currents are passed through an electrode, creating a small region of heat to treat the lesion.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Adult patients (\>/= 18 years)

• Biopsy proven papillary thyroid microcarcinoma (\>/= 1.5cm in greatest diameter, PTMC)

• Either refuse surgery or are not good surgical candidates

Locations
United States
New York
Columbia University
RECRUITING
New York
Contact Information
Primary
Jennifer H Kuo, MD MS
jhk2029@cumc.columbia.edu
212-305-6969
Backup
Vilma Rosario
vr2222@cumc.columbia.edu
Time Frame
Start Date: 2021-11-01
Estimated Completion Date: 2027-11
Participants
Target number of participants: 50
Sponsors
Leads: Columbia University

This content was sourced from clinicaltrials.gov